TherapeuticsMD, Inc. Cash Flow Statement
TXMD|14 years of annual SEC 10-K data (FY2011-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
TherapeuticsMD, Inc. used $23M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$10.3M | $112.0M | -$172.4M | -$176.1M | -$132.6M | -$76.9M | -$89.9M | -$85.1M | -$54.2M | -$28.4M | -$35.1M | -$12.9M | -$12.9M | -$2.9M |
| Depreciation & Amortization | $922.0K | $1.2M | $736.0K | $1.4M | $293.9K | $213.1K | $132.5K | $62.4K | $52.5K | $58.1K | $56.3K | $54.8K | $54.8K | $54.8K |
| Operating Cash Flow | -$23.1M | $9.4M | -$55.1M | -$165.7M | -$106.8M | -$76.2M | -$69.1M | -$79.0M | -$45.5M | -$20.8M | -$12.7M | -$5.0M | -$5.0M | -$5.0M |
| Capital Expenditures | - | - | $34.0K | $2.5M | $217.0K | $61.8K | $396.2K | $165.3K | $31.0K | $40.8K | $66.4K | $28.8K | $28.8K | $28.8K |
| Free Cash Flow | - | - | -$55.2M | -$168.2M | -$107.0M | -$76.2M | -$69.5M | -$79.2M | -$45.6M | -$20.8M | -$12.8M | -$5.0M | -$5.0M | -$5.0M |
| FCF Margin | - | - | -2144.1% | -338.7% | -664.8% | -454.3% | -359.3% | -393.2% | -303.1% | -237.1% | -335.3% | -239.2% | -239.2% | -239.2% |